Back to School With ADHD: Tackling Medication Adherence

Patient: 15-year-old male

Chief Complaint: Inattention, academic inconsistency, and difficulty maintaining medication adherence ahead of start of school year.

History of Present Illness:

The patient presents for a follow-up evaluation as he prepares to enter his junior year of high school next week. Formally diagnosed with attention-deficit/hyperactivity disorder (ADHD) by a psychologist in February 2022, he currently receives accommodations under a 504 plan. Despite these supports, he continues to endorse core symptoms of ADHD, including excessive talking, frequent distractions, and difficulty completing tasks at home. Furthermore, he admits to "zoning out" during exams due to test anxiety, creating a compound barrier to his academic performance.

His mother reports that he struggled significantly with his grades last school year, citing severe inconsistency with daily routines and medication adherence. The patient frequently forgets to take his medication—particularly doses scheduled during the school day—and regularly fails to turn in completed coursework. His historical medication trials include lisdexamfetamine dimesylate and instant-release dextroamphetamine and amphetamine salts. Lisdexamfetamine was discontinued due to low efficacy and "wearing off" effect in early afternoon. While Adderall IR was effective, its multi-dose daily requirement led to frequent missed doses. Most recently, it demonstrated good efficacy when taken consistently near the end of the prior school year, with the patient noting, "I feel like I can focus well in school" when compliant.

Clinical Assessment & Lifestyle Factors:

The patient spent the summer relaxing and participating in organized soccer, an activity he will continue 3 days a week after school this fall. Despite physical activity, lifestyle factors reveal significant structural gaps: his mother notes that "our diet is not great," and the patient struggles with post-school executive functioning, stating, "it’s hard for me to remember to do homework." Vital signs and baseline physical metrics remain within normal limits.

Recommended Answer: Transition to extended-release dextroamphetamine and amphetamine salts at the previously effective dose paired with a daily adherence system (eg., phone alarms, pill organizer) and behavioral interventions for test anxiety.

Rationale:

• Optimizing Compliance & Extended Coverage: Extended-release formulations are first-line for adolescents with adherence challenges because they eliminate the need for in-school dosing—a key friction point for this patient, who frequently forgot daytime doses. The patient previously experienced good symptom control on the medication when taken consistently.
• Targeting Non-Pharmacological Barriers: Changing the molecule does not solve habit formation or executive dysfunction. Combining once-daily extended-release dosing with practical adherence structures (alarms, pill boxes, family-supported routines) directly addresses his primary barrier to success.
• Addressing Co-occurring Test Anxiety: His "zoning out" during exams is tied to performance anxiety rather than primary stimulant failure. Evidence-based behavioral interventions (such as cognitive reframing, grounding techniques, or test-taking accommodations via his 504 plan) target this symptom directly without unnecessarily switching effective ADHD medication.

Why Other Options Are Not Recommended:

• Option B: Returning to short-acting formulation increases dosing frequency to multiple times per day. The history explicitly notes that he struggled with multi-dose regimens and frequently missed afternoon doses.
• Option C: While non-stimulants like atomoxetine can help with anxiety and provide round-the-clock coverage, stimulants remain the gold standard and most effective treatment for ADHD. Given that he tolerated and responded well to Adderall XR, optimizing adherence to a proven effective agent is preferred over switching classes.
• Option D: Discontinuing pharmacotherapy in an adolescent with moderate-to-severe ADHD symptoms and an impending high-stakes academic year (junior year) risks significant academic decompensation. Behavioral and academic accommodations are most effective when combined with optimized pharmacotherapy, not substituted for it.

© 2026 HMP Global. All Rights Reserved.
 
Any views and opinions expressed above are those of the author(s) and do not necessarily reflect the views, policy, or position of the Psych Congress Network or HMP Global, their employees, and affiliates.